- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01025440
An Investigation to Test the Efficacy of the High Flow (HF) Continuous Positive Airway Pressure (CPAP) in Patients With Obstructive Sleep Apnea (OSA)
An Investigation to Test the Efficacy of a Novel CPAP Concept to Reduce the Apnea Hypopnea Index of Patients With Obstructive Sleep Apnea
Phase One:
High Flow (HF) CPAP (HF-CPAP) Titration:
Participants will attend the sleep lab to undergo a comprehensive split-night respiratory PSG. Each participant will be randomized to one of 20 L/min or 35 L/min of CPAP for the first half of the night and swapped to the alternate flow rate for the second half o the night.
At the completion of night 3 participants will be categorized as responders or non-responders. Only responders will continue to Phase 2 of the investigation.
Phase Two:
HF-CPAP compared with CPAP:
Participants will attend the sleep lab to undergo a comprehensive overnight respiratory PSG. Each participant will be randomized to HF-CPAP at a flow rate of 35 L/min or to conventional CPAP at their therapeutic pressure. They will spend the entire night on this treatment arm. Thew following night participants will undergo the alternative treatment arm for the duration of the night.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Each patient will complete a clinical consultation followed by admission to the HELIOS Klinik Hagen-Ambrock facility to undergo routine assessment, diagnosis and CPAP titration (if necessary) of OSA. This will be performed according to the routine clinical care procedures and protocols of the site. The eligibility of each participant will be established during these routine clinical care nights. After night 2 eligible participants will be offered participation in the investigation.
Phase One:
Night 1 (Routine Clinical Care) Participants will attend the HELIOS Klinik Hagen-Ambrock sleep lab to undergo a comprehensive overnight diagnostic PSG, in order to establish the existence and severity of OSA. If the participant has
- a positive diagnosis of OSA with an AHI > 15 events/hr and
- ≥ 90% of all events are Hypopneas they will be eligible to progress to Night 3. Night 2 (Routine Clinical Care) Participants will attend the HELIOS Klinik Hagen-Ambrock sleep lab to undergo a standard CPAP titration, in order to determine their therapeutic CPAP pressure. At this stage, if the participant is eligible, they will be offered participation in the investigation. If potential participants are ineligible or unwilling to participate, they will continue along the routine clinical care path.
Night 3 (Flow Titration) Consented participants will attend the HELIOS Klinik Hagen-Ambrock sleep lab to undergo a comprehensive split-night respiratory PSG.
Each participant will be randomized to one of 20 L/min or 35 L/min of HF-CPAP for the first half of the night. A minimum of three hours on this flow must be recorded on the PSG before participants can be swapped to the alternate flow. Three hours on the alternate flow is also required for this half of the night to be deemed successful.
Responder/Non-responder Determination At the completion of night 3 participants will be categorized as responders or non-responders.
Only responders will continue to Phase 2 of the investigation. A responder is someone who;
- Achieves a > 50% reduction in AHI and
- Achieves an RDI < 10 events/hr. Investigation Break Before responders progress to Phase Two participants will be sent home for 1 week. During this time they will be instructed to undertake CPAP treatment. Their CPAP device will be set to their therapeutic pressure which was determined on Night 2.
Phase Two:
Night 4 (HF-CPAP compared with CPAP) Participants will attend the HELIOS Klinik Hagen-Ambrock sleep lab to undergo a comprehensive overnight respiratory PSG.
Each participant will be randomized to OpenCPAP at a flow rate of 35 L/min or to conventional CPAP at their therapeutic pressure. They will spend the entire night on this treatment arm.
Night 5 (HF-CPAP compared with CPAP) Participants will attend the HELIOS Klinik Hagen-Ambrock sleep lab to undergo a comprehensive overnight respiratory PSG.
Participants will be swapped to the alternative treatment arm, either HF-CPAP at a flow rate of 35 L/min or to conventional CPAP at their therapeutic pressure. They will spend the entire night on this treatment. In the morning at completion of the PSG, participants will be asked which treatment Night (4 or 5) they preferred.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Hagen
-
Ambrocker Weg 60, Hagen, Germany, D 58091
- HELIOS-Klinik Hagen Ambrock
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged ≥ 18 years.
- AHI > 15 events per hour and ≥ 90% of events must be Hypopneas.
Exclusion Criteria:
- Any medical condition which contraindicates the use of CPAP or AutoCPAP. See Appendix D for this list.
- Requires supplemental oxygen.
- Unstable cardiovascular disease (untreated or resistant hypertension acceptable).
- Unstable psychiatric disease.
- Other significant sleep disorder.
- Inability to tolerate CPAP due to nasal obstruction or claustrophobia, as determined by the investigation investigator.
- Any known factor or disease that might interfere with treatment compliance, investigation conduct or interpretation of the results such as psychiatric disease, history of non compliance to medical regimens, or unwillingness to comply with investigational requirements.
- Participation in another clinical investigation in the previous month.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: CPAP
Continuous Positive Airway Pressure (CPAP) is the gold-standard treatment for OSA. CPAP mechanically splints the upper airway open during sleep to prevent collapse and in this way ameliorates OSA. Dose: The CPAP pressure will be set to the individual subject's therapeutic pressure -as determined by PSG on Night 2. Duration: 1 night - the duration of the subject's sleep period (minimum of 3 hrs of sleep required) |
Continuous Positive Airway Pressure (CPAP) Dose: A flow (35 L/min) or pressure (btw 4 and 20 cmH20 -individual to each subject) is set on the device. Duration: 1 night - the duration of the subject's sleep period (minimum of 3 hrs of sleep required) Duration:
Other Names:
|
ACTIVE_COMPARATOR: HFCPAP
Continuous Positive Airway Pressure (CPAP) is the gold-standard treatment for OSA. CPAP mechanically splints the upper airway open during sleep to prevent collapse and in this way ameliorates OSA. Dose: During HF CPAP 35 L/min wil be administered. Duration: 1 night - the duration of the subject's sleep period (minimum of 3 hrs of sleep required) |
Continuous Positive Airway Pressure (CPAP) Dose: A flow (35 L/min) or pressure (btw 4 and 20 cmH20 -individual to each subject) is set on the device. Duration: 1 night - the duration of the subject's sleep period (minimum of 3 hrs of sleep required) Duration:
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Efficacy to treat OSA
Time Frame: Nights 3, 4 and 5 (after each PSG)
|
Nights 3, 4 and 5 (after each PSG)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Sleep Quality
Time Frame: Nights 3, 4 and 5 (after each PSG)
|
Nights 3, 4 and 5 (after each PSG)
|
Participant Treatment Preference: HF-CPAP compared with CPAP
Time Frame: Night 5
|
Night 5
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: George Nilius, M.D, HELIOS-Klinik Hagen Ambrock
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FPHC LP-CPAP09-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obstructive Sleep Apnea
-
LivaNovaRecruitingApnea | Obstructive Sleep Apnea | OSA | Apnea, Obstructive | Apnea+Hypopnea | Apnea, Obstructive Sleep | Hypopnea, SleepUnited States
-
Mauro ManconiCompletedObstructive Sleep Apnea Syndrome | Sleep Apnea, Obstructive | Obstructive Sleep Apnea | OSA | Apnea, Obstructive | OSAHSwitzerland
-
University of California, Los AngelesRecruiting
-
Brigham and Women's HospitalCompletedObstructive Sleep Apnea (OSA)United States
-
State Budgetary Healthcare Institution, National...RecruitingObstructive Sleep Apnea | Obstructive Sleep Apnea-hypopnea | Obstructive Sleep Apnea-hypopnea SyndromeRussian Federation
-
ApnimedCompletedOSA - Obstructive Sleep ApneaUnited States
-
ResMedCompletedObstructive Sleep Apnea (OSA)United States, Australia
-
The Hospital for Sick ChildrenCompleted
-
Cryosa, Inc.Active, not recruitingObstructive Sleep Apnea of AdultPanama, Paraguay
Clinical Trials on Continuous Positive Airway Pressure
-
University Hospital, GrenobleResMed; Société francophone de pneumologie de langue francaiseCompletedType 1 Diabetes | Sleep Apnea SyndromeFrance
-
University Hospital, MontpellierCompletedCoronary Artery Disease | Sleep Apnea SyndromeFrance
-
Sanjay R PatelBeth Israel Deaconess Medical Center; National Institutes of Health (NIH); Brigham...CompletedSleep Apnea, Obstructive | Diabetes MellitusUnited States
-
Chinese Pulmonary Vascular Disease Research GroupCompletedObstructive Sleep Apnea | Coronary Heart DiseaseChina
-
Poitiers University HospitalCompletedObstructive Sleep Apnea Syndromes
-
Indiana UniversityNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
University Hospital, MontpellierUnknownObstructive Sleep Apnea Syndrome | Brain InfarctionFrance
-
Eileen R. ChasensCompletedSleep Apnea, Obstructive | Diabetes Mellitus, Type 2United States
-
Fondazione Policlinico Universitario Agostino Gemelli...CompletedSleep Apnea, Obstructive | Fatigue | SarcoidosisItaly
-
Sociedad Española de Neumología y Cirugía TorácicaCompletedObstructive Sleep ApneaSpain